Emergent Biosolutions Inc(EBS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:01 PM ET (Korea 10/31 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.55 | Insider Own | 5.96% | Shs Outstand | 51.3M | Perf Week | 9.31% |
| Market Cap | 0.35B | Forward P/E | 6.51 | EPS next Y | 190.99% | Insider Trans | -2.73% | Shs Float | 48.2M | Perf Month | 6.91% |
| Enterprise Value | 0.80B | PEG | 7.84 | EPS next Q | -0.39 | Inst Own | 88.09% | Short Float | 20.09% | Perf Quarter | -8.1% |
| Income | -0.18B | P/S | 0.45 | EPS this Y | -76.5% | Inst Trans | 3.23% | Short Ratio | 7.95 | Perf Half Y | -19.6% |
| Sales | 0.77B | P/B | 1.02 | EPS next 5Y | 0.83% | ROA | -13.95% | Short Interest | 9.68M | Perf YTD | -44.9% |
| Book/sh | 6.65 | P/C | 2.48 | EPS past 3/5Y | - -30.38% | ROE | -40.29% | 52W High | -51.56% ($14.06) | Perf Year | -46.96% |
| Cash/sh | 2.75 | P/FCF | 4.06 | Sales past 3/5Y | -12.72% -13.74% | ROIC | -19.05% | 52W Low | 56.19% ($4.36) | Perf 3Y | 235.47% |
| Dividend Est. | - | EV/EBITDA | 3.42 | EPS Y/Y TTM | -231.68% | Gross Margin | 47.17% | Volatility(W/M) | 5.97% 5.96% | Perf 5Y | -85.71% |
| Dividend TTM | - | EV/Sales | 1.03 | Sales Y/Y TTM | -9.56% | Oper. Margin | 17.77% | ATR (14) | 0.38 | Perf 10Y | -74.68% |
| Dividend Ex-Date | - | Quick Ratio | 2.95 | EPS Q/Q | -1477.33% | Profit Margin | -22.96% | RSI (14) | 52.98 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.42 | Sales Q/Q | 66.29% | SMA20 | 0.94% ($6.75) | Beta | 2.38 | Target Price | $11 |
| Payout | - | Debt/Eq | 1.72 | Earnings | 2026/11/2 | SMA50 | 5.23% ($6.47) | Rel Volume | 0.62 | Prev Close | $7.22 |
| Employees | 900 | LT Debt/Eq | 1.72 | EPS/Sales Surpr. | 805.88% 32% | SMA200 | -15.02% ($8.01) | Avg Volume(3M) | 1.22M | Price | $6.81 |
| IPO | 2006/11/15 | Option/Short | Yes/Yes | Trades | 5637 | Volume | 754,456 | Change | -5.68% |
💉 Naltech Spray Naloxone (Narcan) and medical countermeasures for anthrax, smallpox, and other threats. Founded in 1987, the company is a U.S. specialty and generic pharmaceutical firm that supplies vaccines and antidotes for government stockpiles, as well as nerve agent treatments. Leveraging its manufacturing capabilities for government-procured vaccines and antidotes and its regulatory approval expertise, the company has established a strong position in the public health preparedness market.
Over the past 1 year, roughly in the middle
52% below its 1-year high.
Traded less than usual. That is 62% of its average volume.
Next earnings report: November 2
1 days to go.
EBS keeps an operating profit but posts a net loss
Of every $100 in sales, $17.77 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -76.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $45. Peers typically go for $158. Compared with its own 2-year average, it is 28% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -85.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.1% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #43 of 83 in the industry
Based on market cap of $349M.
KMDA#41 Kamada Ltd $444M PER 20.2 
TLRY#42 Tilray Brands Inc $374M PER - EBS#43 Emergent Biosolutions Inc $349M PER - 
ANIK#44 Anika Therapeutics Inc $280M PER - 
CGC#45 Canopy Growth Corp $274M PER - 
FAQ
What kind of company is EBS?
EBS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of EBS?
The market cap of EBS is approximately $349M, ranking 3,474 within its sector.
What is the 52-week high and low for EBS?
EBS has recorded a 52-week high of $14.06 and a low of $4.36.
